Colorectal cancer trial endpoints: time for dynamic thinking?

Affiliations

¹ Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK.
² Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK. Electronic address: ian.chau@rmh.nhs.uk.

Comment

Michael Davidson et al. Lancet Oncol. 2016 Oct.

. 2016 Oct;17(10):1345-1347.

doi: 10.1016/S1470-2045(16)30443-0.

¹ Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK.
² Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK. Electronic address: ian.chau@rmh.nhs.uk.

No abstract available

Comment on

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators. Stintzing S, et al. Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Lancet Oncol. 2016. PMID: 27575024 Clinical Trial.